Topics

Protein Glutamine Gamma Glutamyltransferase 2 Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13 Pipeline Review, H1 2019 [Published by Global Markets Direct] Prices from

08:30 EDT 14 Aug 2019 | BioPortfolio Reports

Protein Glutamine Gamma Glutamyltransferase 2 Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13 Pipeline Review, H1 2019


Summary


According to the recently published report 'Protein Glutamine Gamma Glutamyltransferase 2 Pipeline Review, H1 2019'; Protein Glutamine Gamma Glutamyltransferase 2 Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13 pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.


Protein Glutamine Gamma Glutamyltransferase 2 Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13 Transglutaminase 2 TG2 is a member of the transglutaminase family that catalyzes calciumdependent posttranslational modification of proteins by inserting highly stable isopeptide bonds between polypeptide chains or by conjugating polyamines to proteins. TG2 also exhibits GTPase activity and can serve as a signaltransduction G protein.


The report 'Protein Glutamine Gamma Glutamyltransferase 2 Pipeline Review, H1 2019' outlays comprehensive information on the Protein Glutamine Gamma Glutamyltransferase 2 Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.


It also reviews key players involved in Protein Glutamine Gamma Glutamyltransferase 2 Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Infectious Disease, Oncology and Respiratory which include indications Celiac Disease, Burkholderia Infections, Cystic Fibrosis, Pseudomonas aeruginosa Infections and Renal Cell Carcinoma.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Protein Glutamine Gamma Glutamyltransferase 2 Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13

The report reviews Protein Glutamine Gamma Glutamyltransferase 2 Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Protein Glutamine Gamma Glutamyltransferase 2 Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13 targeted therapeutics and enlists all their major and minor projects

The report assesses Protein Glutamine Gamma Glutamyltransferase 2 Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Protein Glutamine Gamma Glutamyltransferase 2 Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Protein Glutamine Gamma Glutamyltransferase 2 Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Protein Glutamine Gamma Glutamyltransferase 2 Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Protein Glutamine Gamma Glutamyltransferase 2 Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13 Pipeline Review, H1 2019 [Published by Global Markets Direct] Prices from

NEXT ARTICLE

More From BioPortfolio on "Protein Glutamine Gamma Glutamyltransferase 2 Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13 Pipeline Review, H1 2019 [Published by Global Markets Direct] Prices from"

Quick Search

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...